Advances in the treatment of multiple myeloma: the role of thalidomide
Data
2003-01-01
Autores
Ribas, Christian 
Colleoni, Gisele Wally Braga
Tipo
Artigo
Título da Revista
ISSN da Revista
Título de Volume
Resumo
Multiple myeloma (MM) accounts for 1% of all malignancies and 10% of malignant hematological neoplasms. in spite of high-dose therapy with stem cell rescue, relapse and disease resistance are common events in the course of the disease. Thalidomide (Thal) has been successfully used in such situations and it's use has also been expanded to the up-front therapy and as adjuvant to stem cell transplantation. Here, we review the underlying concepts and current clinical data regarding Thal in the treatment of MM.
Descrição
Citação
Leukemia & Lymphoma. Abingdon: Taylor & Francis Ltd, v. 44, n. 2, p. 291-298, 2003.